In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 981-987

  Izbicka, E ^a,d   Lawrence, R ^a   Raymond, E ^b   Eckhardt, G ^a   Faircloth, G ^b   Jimeno, J ^b   Clark, G ^c   Von Hoff, D D ^a  

^a CTRC Institute for Drug Development   (United States)

^b PHARMAMAR S A   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Cloning assay; Ecteinascidins; Minor groove binding agents; Tetrahydroisoquinolone alkaloids

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; NCS 648766; PACLITAXEL; TRABECTEDIN; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL CYCLE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL;

EID: 0031766324     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008224322396     Document Type: Article

References (38)

1. Sakai R, Rinehart KL, Guan KL et al. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo. Proc Natl Acad Sci USA 1992; 89: 11456-60.
2. Moore BM, Seaman FC, Hurley LH. The NMR model of an ecteinascidin 743-DNA adduct. Proc Am Assoc Cancer Res 1997; 38: 314.
3. Erba E, Balconi G, Faretta M. Cell cycle phase perturbations induced by new natural marine compounds, Proc NCI/EORTC Symp New Drugs Cancer Ther 1996; 82.
4. Garcia-Rocha MA, Gravalos MD, Aliva J. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: Ecteinascidin 743, isohomohalichrondrin-B and LL-15. Br J Cancer 1996; 73: 875-83.
5. Rinehart KL, Gravalos LG, Faircloth G et al. Preclinical antitumor development of a marine derived natural product. Proc Am Assoc Cancer Res 1995; 36: 390.
6. Jimeno JJ, Faircloth G, Cameron L et al. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs Future 1996; 21: 1155-65.
7. Eckhardt SG, Degen D, Ortiz V et al. In vitro studies of a novel marine cytotoxic, ecteinascidin (ET-743). Ann Oncol 1996; 7: 131.
8. Eckhardt SG, Degen D, Faircloth et al. Activity of ecteinascidin, a novel marine cytotoxic, against primary human tumor colony-forming units. Proc Am Assoc Cancer Res 1996; 37: 409.
9. Hamburger AW, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 1977; 60: 846-57.
10. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461.
11. Von Hoff DD, Casper J, Bradley E et al. Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 1981; 70: 1027-32.
12. Von Hoff DD, Coltman CA Jr, Forseth B. Activity of Mitoxantrone in a human tumor cloning system. Cancer Res 1981; 41: 1853-5.
13. Shoemaker RH, Wolpert-Defillipes MK, Kern DH et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2145-53.
14. Von Hoff DD, Huong AM, Collins J. Effect of recombinant Beta Interferon (r-IFN-bser) on primary human tumor colony forming units. J Interferon Res 1988; 8: 813-20.
15. Foulke RS, Marshall MH, Trotta PP et al. In vitro assessment of the effects of granulocyte-macrophage colony stimulating factor on primary human tumors and derived lines. Cancer Res. 1990; 50: 6264-7.
16. Hanauske AR, Degen D. Marshall MH et al. Effects of recombinant human interleukin-1a on clonogenic growth of primary human tumors in vitro. J Immunol 1992; 11: 155 8.
17. Von Hoff DD, Marshall MH, Heimbrook DC et al. Activity of a recombinant transforming growth factor-a-pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units. Invest N Drugs 1992; 10: 17-22.
18. Hanauske AR, Degen D, Marshall MH et al. Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs 1992; 3: 143-6.
19. Hanauske AR, Degen D, Trotta PP et al. Effects of recombinant human interleukin-4 on in vitro colony formation of freshly explanted human tumor cells. Invest N Drugs 1992; 10: 269-73.
20. Burris HA III, Hanauske AR, Marshall MH et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in vitro. J Natl Cancer Inst 1992; 84: 1816-20.
21. Shimada Y, Rothenberg M, Hilsenbeck SG et al. Activity of CPT-11 (irinotecan hydrochloride). a topoisomerase I inhibitor, against human tumor colony-forming units. Anti-Cancer Drugs 1994; 5: 202 6.
22. Izquierdo MA, Degen D, Myers L et al. Effects of the hematopoietic growth factors GM-CSF. IL-3, and IL-6 on human tumor colony-forming units taken directly from patients. Ann Oncol. 1995; 6: 927-32.
23. Ebrahim El-Zayat AA, Izquierdo MA, Clark GM et al. Activity of the morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro. Invest N Drugs 1996; 13: 125 31.
24. Izbicka E, Lawrence R, Cerna C et al. Activity of TER286 against human tumor colony forming units. Anti-Cancer Drugs 1997; 8: 345-8.
25. Raymond E, Hanauske A, Faivre S et al. Effects of prolonged versus short term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anti-Cancer Drugs 1997; 8: 1 7.
26. Dorr RT, Von Hoff DD, Daunorubicin HCI. Cancer Chemotherapy Handbook, 2nd edition. Norwalk, Connecticut: Appleton and Lange 1994; 355 64.
27. Dorr RT, Von Hoff DD, Plicamycin. Cancer Chemotherapy Handbook, 2nd edition. Norwalk, Connecticut: Appleton and Lange 1994; 797-801.
28. Faircloth G, Rinehart K, Avila J et al. ET-743: A marine compound with significant in vivo activity in early and advanced breast cancer models. Proc Intern Symp Changes Treat Breast Cancer 1995; Abstr 1.
29. Giavazzi R, Valoti G, Faircloth G. Antitumor activity of ET-743: A marine natural product on human ovarian carcinoma xenografts. Proc 1st Eur Symp Ovarian Cancer 1996; Abstr. 04.
30. Hendricks HR, Febig HH, Giavazzi R et al. ET-743 in human tumor xenograft models. Proc Am Assoc Cancer Res 1996; 37: Abstr 2653.
31. Faircloth G, Hendricks HR, Giavassi R et al. In vivo antitumor activity of Ecteinascidin-743 (ET-743). a novel marine derived cytotoxic against human xenografts tumor models. Ann Oncol 2996; 7: 125.
32. Moyzis RK, Buckingham JM, Cram SCL et al. A highly conserved repetitive DNA sequence. (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988; 85: 6622 6.
33. Blackburn E. Structure and function of telomeres. Nature. 1991; 350: 569-73.
34. Harley CK. Telomere loss: Mitotic clock or genetic time bomb? Mutation Res 1991; 256: 271-82.
35. Parkinson EK. Do telomerase antagonists represent a novel anti-cancer strategy? Br J Cancer 1996; 73: 1-4.
36. Wheelhouse RT, Sun D, Hurley LH. Non-nucleotide telomerase inhibitors: Structure-based design of G-quadruplex interactive agents. Proc Am Assoc Cancer Res 1997; 38: 637.
37. Sun D, Thompson B, Salazar M et al. Human telomerase inhibition of G-tetraplex interactive compounds. Proc Am Assoc Cancer Res 1997; 38: 637.
38. Izbicka E, Raymond E, Sun D et al. Evaluation of the cytotoxic effects of novel telomerase inhibitors in vitro. Proc Am Assoc Cancer Res 1997; 38: 637.